If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-09. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Males and females are affected equally. The disease was discovered in 1934 by Ivar Asbjørn Følling, with the importance of diet determined in 1935. As of 2023, genetic therapies that aim to directly restore liver PAH activity are a promising and active research field.
Xylem tissue is organised in a tube-like fashion along the main axes of stems and roots. It consists of a combination of parenchyma cells, fibers, vessels, tracheids, and ray cells. Longer tubes made up of individual cells are vessels, while vessel members are open at each end. Internally, there may be bars of wall material extending across the open space. These cells are joined end-to-end to form long tubes. Vessel members and tracheids are dead at maturity. Tracheids have thick secondary cell walls and are tapered at the ends. They do not have end openings such as the vessels. The end overlap with each other, with pairs of pits present. The pit pairs allow water to pass from cell to cell. Though most conduction in xylem tissue is vertical, lateral conduction along the diameter of a stem is facilitated via rays. Rays are horizontal rows of long-living parenchyma cells that arise out of the vascular cambium.
The Agriculture Improvement Act of 2018 allows hemp-derived products with ≤0.3% Δ9-THC to be sold legally in the US, leading to widespread availability of cannabinoids like Δ8-THC, Δ10-THC, HHC, and THCP. These compounds lack the extensive research of Δ9-THC, posing potential risks and challenges for drug testing due to novel metabolites and high potency (e.g., THCP's 33× binding affinity). A 2023 paper proposed the term "derived psychoactive cannabis products" to distinguish these substances.
Sources: en.wikipedia.org
== Medical uses == The primary measure of efficacy in the clinical trials is three or more spontaneous complete bowel movements per week; a secondary measure is an increase of at least one complete spontaneous bowel movement per week. Further measures are improvements in PAC-QOL (a quality of life measure) and PAC-SYM (a range of stool, abdominal, and rectal symptoms associated with chronic constipation). Infrequent bowel movements, bloating, straining, abdominal pain, and defecation urge with inability to evacuate can be severe symptoms, significantly affecting quality of life. In three large clinical trials, 12 weeks of treatment with prucalopride 2 and 4 mg/day resulted in a significantly higher proportion of patients reaching the primary efficacy endpoint of an average of ≥3 spontaneous complete bowel movements than with placebo. There was also significantly improved bowel habit and associated symptoms, patient satisfaction with bowel habit and treatment, and HR-QOL in patients with severe chronic constipation, including those who did not experience adequate relief with prior therapies (>80% of the trial participants). The improvement in patient satisfaction with bowel habit and treatment was maintained during treatment for up to 24 months; prucalopride therapy was generally well tolerated. Small clinical trials suggested that prucalopride administration results in the 5-HT4 receptor agonism-associated memory enhancing in healthy participants improving their ability to recall and increasing neural activation in the hippocampus and functionally related areas.
Per Baseball Reference, Bagwell's 79.6 Wins Above Replacement (WAR) ranks sixth-most all-time among first basemen, trailing only Lou Gehrig, Albert Pujols, Jimmie Foxx, Cap Anson, and Roger Connor. He spent the first nine seasons of his career (1991–99) playing home games at the Astrodome, notorious for its reputation as the toughest park in which to hit when baseball was still played there. However, during those nine years, his production at home was nearly identical to his production on the road. In that same period of time, his 160 OPS+ was fourth behind Bonds, McGwire, and Frank Thomas; his 56.7 WAR was third behind Bonds and Ken Griffey Jr. From 1994 to 2000, a span including his age-26 through age-32 seasons, he averaged 41 home runs and 41 doubles per 162 games while batting .309, .433 OBP, and .593 SLG for a 167 OPS+. Over his career, Bagwell batted at least .300 six times, amassed a 1.000 OPS five times, collected at least 30 home runs eight times, 100 RBI eight times, 100 runs scored nine times, and 100 walks seven times. He is the only player in history to achieve six consecutive seasons (1996–2001) with each of 30 home runs, 100 RBI, 100 runs scored, and 100 walks. Bagwell had seven seasons with 30 home runs and 100 walks; the only players with more are Gehrig, Ruth, Williams, Jim Thome, and Thomas. Bagwell is one of 12 players in MLB history to hit at 400 home runs and attain a career on-base percentage of at least .400. The only National League first baseman to reach the 30–30 club, he is the only first baseman in history to do it twice.
Founding the Biomedical Engineering Society's Diversity Committee. Co-founding KEYs (Keys to Empowering Youth), a program that brings middle-school girls to visit high-tech labs to encourage their interest in science and technology. Chairing the Institute of Medical Engineering and Science Diversity Committee at MIT. Serving on the Faculty Gender Equity Committee at the MIT School of Engineering and advising the MIT Society of Women Engineers. Bhatia's advocacy and groundbreaking work have made her a public figure, featured in diverse media. She has been named one of Fast Company's Most Creative People (2014) and a Foreign Policy's leading global thinker. Her inspiring story has been featured on TV Nova Science Now, in the film Picture a Scientist, and in various books and podcasts. She's even been rendered as a LEGO minifigure and recognized among Vogue India's Incredible Women, showcasing her broad impact and visibility. Bhatia and her over 85 trainees have contributed to more than 230 peer-reviewed scientific papers and more than 65 issued or pending patents over twenty years. As of 2025, Bhatia has launched 8 biotechnology companies at the intersection of medicine and miniaturization. About three-quarter of her former postdoctoral trainees are current academic faculty members (half of which are already tenured), while a quarter of her 39 Ph.D. graduates are academic faculty members and another quarter hold Director or C-suite roles in biotech and pharma companies.
== Further reading == Collins R (2017). "Lowering Restrictions on Performance Enhancing Drugs in Elite Sports". Inquiries Journal. 9 (3). Retrieved 7 July 2017. Franke WW, Berendonk B (July 1997). "Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government". Clinical Chemistry. 43 (7): 1262–79. doi:10.1093/clinchem/43.7.1262. PMID 9216474. Mottram, David (2005); Drugs in Sport, Routledge. ISBN 978-0-415-37564-1. Murray, Thomas H. (2008); "Sports Enhancement", in From Birth to Death and Bench to Clinic: The Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns. Pope J, Harrison G, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S (2014). "Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement". Endocrine Reviews. 35 (3): 341–375. doi:10.1210/er.2013-1058. PMC 4026349. PMID 24423981. Waddington and Smith (2008); An Introduction to Drugs in Sport, Routledge. ISBN 978-0-415-43125-5. Collins R (2017). "Lowering Restrictions on Performance Enhancing Drugs in Elite Sports". Inquiries Journal. 9 (3). Retrieved 7 July 2017. Toby M (2024). The History of Performance-Enhancing Drugs In Thoroughbred Racing. University of Kentucky Press. ISBN 9780813197975.
Sources: en.wikipedia.org
== Effects of the Closure == Madera Community Hospital was the only hospital within a 30 mile radius, thus the closure caused 160,000 Madera residents to not have access to a local emergency room. Many people were faced with driving the 45 minutes to one of the neighboring towns or not receiving proper treatment. Unfortunately, this decision was already made for residents without access to a vehicle or public transportation. Other hospitals in the Central Valley were then stressed by the pressures of taking on all of the patients who would have previously been treated in Madera, which caused significant increases in emergency room wait times. Private ambulance companies from other counties pitched in to help take calls from Madera to transport residents to other hospitals such as Saint Agnes Medical Care (Fresno) and Community Regional Medical Center (Fresno). Not only were the patients redirected, 772 employees across the four locations were laid off when the hospital shuttered its doors.
== Erinacine C == Erinacine C has also been observed to activate the transcription factor Nrf2 and has been observed to play a role in neurogenesis and neuroplasticity. Stimulator of NGF synthesis in vitro((299.1 ± 59.6) pg/mL at 1.0 mmol/L)
Initial clinical trial results with IgG4 PD1 antibody nivolumab were published in 2010. It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. Pembrolizumab (Keytruda) is another PD1 inhibitor that was approved by the FDA in 2014. Pembrolizumab is approved to treat melanoma and lung cancer. Antibody BGB-A317 is a PD-1 inhibitor (designed to not bind Fc gamma receptor I) in early clinical trials.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.